{"id":"W4385949824","doi":"10.3389/fonc.2023.1223282","title":"Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms","year":2023,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"National Cancer Institute; Eisai; Memorial Sloan-Kettering Cancer Center","keywords":"Lenvatinib; Medicine; Sunitinib; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Kidney cancer; Everolimus; Nephrectomy; Urology; Sorafenib; Cancer; Kidney; Immunotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004425863,0.0002640434,0.0008119239,0.0005275764,0.0000594051,0.0000097039,0.0001471835,0.0001293937,0.000007670161],"category_scores_gemma":[0.0001066201,0.000175302,0.00005492874,0.000545362,0.0001434154,0.00007727425,0.00007807781,0.0003583062,0.000003539082],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007567777,"about_ca_system_score_gemma":0.0002063616,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001967047,"about_ca_topic_score_gemma":0.0008871889,"domain_scores_codex":[0.9980573,0.0001896177,0.0005030404,0.0004776177,0.0002426152,0.0005298117],"domain_scores_gemma":[0.9989138,0.0004448738,0.0001412965,0.0003427783,0.00006044463,0.00009685864],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01301575,0.003058886,0.9628195,0.00005044755,0.00005080257,0.0004009847,0.003976289,0.0001105369,0.00001836934,0.000004085361,0.0006792536,0.01581508],"study_design_scores_gemma":[0.09561644,0.0177962,0.8781959,0.00002326931,0.00008911172,0.000004122293,0.006763136,0.0006760929,0.00008537525,0.00003948184,0.0005532375,0.0001576673],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946204,0.0002306121,0.00005025557,0.0005616643,0.0003441502,0.003854703,0.00002664858,0.00002896213,0.0002825723],"genre_scores_gemma":[0.9969737,0.00003058026,0.001731672,0.0001505753,0.0000312,0.0006835333,0.00009524673,0.0000452042,0.0002582954],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08462364,"threshold_uncertainty_score":0.7148608,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02308070190058515,"score_gpt":0.3056554367024069,"score_spread":0.2825747348018217,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}